Benuvia Signs Licensing Deal with Avernus Pharma for SYNDROS in GCC Region

• Benuvia Operations, LLC has entered a licensing agreement with Avernus Pharma for SYNDROS distribution in the GCC region.

• SYNDROS (dronabinol), an FDA-approved liquid cannabinoid, addresses chemotherapy-induced nausea and AIDS-related anorexia.

Benuvia Operations, LLC, a global CDMO, has announced a licensing partnership with Avernus Pharma, granting Avernus exclusive distribution rights for SYNDROS in the Gulf Cooperation Council (GCC) region. This encompasses Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the UAE, pending GCC-DR approval.

SYNDROS is the first FDA-approved liquid cannabinoid (CII) used to treat chemotherapy-induced nausea and vomiting and anorexia in AIDS patients. Terry Novak, CEO of Benuvia, emphasised the collaboration’s potential to expand patient access in the region, noting Avernus’ strong local reputation.

“The signing of SYNDROS marks a groundbreaking moment for chemotherapy patients across the GCC, symbolizing a new era of hope and innovation in oncology care,” said Dr. Ziad Amir Saleh, CEO of Avernus Pharma & Al Ain Medical Store. Echoing this sentiment Dr. Malath Jamous, Director of Avernus Pharma, added, “This is more than a licensing agreement—it’s a monumental step forward in our mission to transform the lives of patients battling the harsh side effects of chemotherapy. By adding SYNDROS (dronabinol), the first and only FDA-approved Schedule II liquid THC, to our oncology portfolio, we are not only expanding our capabilities but also redefining what’s possible in patient care. Our partnership with Benuvia paves the way for local approval of SYNDROS, a beacon of relief and innovation, and we are honored to bring this important medication to those who need it most.”